Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Cerulean Pharma Inc. Announces Appointment of Oliver S. Fetzer as President and

Abstract:
Cerulean Pharma Inc., a biopharmaceutical company focused on novel, intelligently designed, nanoparticle-based drugs, announced today that Oliver S. Fetzer has been named as President and Chief Executive Officer. He has also been elected to the Company's board of directors. Dr. Fetzer will succeed Alan L. Crane, who has been named Chairman of the board of directors.

Cerulean Pharma Inc. Announces Appointment of Oliver S. Fetzer as President and

Cambridge, MA | Posted on April 10th, 2009

Dr. Fetzer has a diverse background in biotechnology and healthcare. Most recently, he was Senior Vice President, Corporate Development and Research and Development at Cubist Pharmaceuticals. While at Cubist his responsibilities included Corporate Development, Business Development, Drug Discovery Research, Non-Clinical Development, Clinical Development, Chemical Development, Medical Affairs and Program Management.

Prior to joining Cubist, Oliver served as a Managing Director and Partner at the Boston Consulting Group in the firm's healthcare practice where he was responsible for projects in strategy, operational effectiveness, and mergers and integration.

Dr. Fetzer worked at Bayer AG early in his career where he was involved in chemistry and pharmaceutics. He is a director of Auxilium Pharmaceuticals (NASDAQ: AUXL) and holds a Ph.D. in Pharmaceutical Sciences from the Medical University of South Carolina and an MBA from Carnegie Mellon University. "I am very excited about joining Cerulean" said Dr. Fetzer. "The opportunity to develop a technology and grow a company with such broad implications for the pharmaceutical industry and to do it with an absolutely world-class team is truly exceptional." "We are extremely pleased that Oliver Fetzer will be assuming the role of CEO at Cerulean," said Alan Crane, Chairman of the board of Cerulean. "As we move our first products towards the clinic and further demonstrate the power of our nanopharmaceutical platform, Oliver's leadership, strategic and operational skills across science and business will be invaluable."

In addition to serving as Chairman of Cerulean, Mr. Crane will assume the role of General Partner at Polaris Venture Partners, where he has been a Venture Partner since 2002.

####

About Cerulean Pharma
Cerulean Pharma Inc. is a privately-held biopharmaceutical company focused on the development of novel, nanotechnology-based therapeutics in the areas of oncology, cardiovascular, autoimmune and inflammatory diseases. The Company has assembled a world-class management team, board of directors and scientific advisory board that collectively have a significant track record of business building, product development and scientific breakthroughs from companies and institutions such as Millennium Pharmaceuticals, Pfizer, GlaxoSmithKline, the Massachusetts Institute of Technology, Harvard Medical School, MD Anderson, Fox Chase Cancer Center and the Arizona Health Center. The company has been funded by leading investors Polaris Venture Partners, Venrock, Lux Capital, Bessemer Venture Partners, Alexandria Real Estate Equities, and William H. Rastetter. Cerulean is located in Cambridge, Massachusetts.

For more information, please click here

Contacts:
Cerulean Pharma, Inc.
161 First Street
Cambridge, MA 02142
Tel 617-551-9600
Fax 617-494-1544

Copyright © Cerulean Pharma

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related Links

Cerulean Pharma

Related News Press

News and information

MRI, on a molecular scale: Researchers develop system that could one day peer into the atomic structure of individual molecules April 20th, 2014

Iranian Researchers Present New Model to Strengthen Superconductivity at Higher Temperatures April 19th, 2014

Iranian Researchers Produce New Anti-Cancer Drug from Turmeric April 19th, 2014

Innovative strategy to facilitate organ repair April 18th, 2014

Announcements

MRI, on a molecular scale: Researchers develop system that could one day peer into the atomic structure of individual molecules April 20th, 2014

Iranian Researchers Present New Model to Strengthen Superconductivity at Higher Temperatures April 19th, 2014

Iranian Researchers Produce New Anti-Cancer Drug from Turmeric April 19th, 2014

Innovative strategy to facilitate organ repair April 18th, 2014

Appointments/Promotions/New hires/Resignations/Deaths

Nanobiotix Appoints Thierry Otin as Head of Manufacturing and Supply April 15th, 2014

Industry Veteran Fergus Clarke Joins Picodeon as CEO: Appointment comes as Picodeon prepares for growth April 8th, 2014

Peter B. Littlewood appointed Director of Argonne National Laboratory March 26th, 2014

Global 450 consortium announces new general manager of internal operations: TSMC’s Cheng-Chung Chien Receives Unanimous Support, Brings History of Innovation and Efficiency to Global Consortium of Companies Driving Industry Transition to 450mm Wafer Technology March 26th, 2014

NanoNews-Digest
The latest news from around the world, FREE







  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE